PLoS ONE · 2012 · 21 citations · 39 references
MedicineOncologyPharmacologyDrug DeliveryMolecular OncologyTumor MicroenvironmentAngiogenesisAngiogenesis In CancerTumor Microenvironment ModulationTargeted DeliveryTumor Targeting LigandsTumor Targeting SpecificityTumor Vasculature TargetingTumor-targeting PeptidesVascular Endothelial Growth FactorVascular Targeting
BACKGROUND: Blood vessels in tumors express higher level of aminopeptidase N (APN) than normal tissues. Evidence suggests that the CNGRC motif is an APN ligand which targets tumor vasculature. Increased expression of APN in tumor vascular endothelium, therefore, offers an opportunity for targeted delivery of NGR peptide-linked drugs to tumors. METHODS/PRINCIPAL FINDINGS: To determine whether an additional cyclic CNGRC sequence could improve endothelial cell homing and antitumor effect, human plasminogen kringle 5 (hPK5) was modified genetically to introduce a CNGRC motif (NGR-hPK5) and was subsequently expressed in yeast. The biological activity of NGR-hPK5 was assessed and compared with that of wild-type hPK5, in vitro and in vivo. NGR-hPK5 showed more potent antiangiogenic activity than wild-type hPK5: the former had a stronger inhibitory effect on proliferation, migration and cord formation of vascular endothelial cells, and produced a stronger antiangiogenic response in the CAM assay. To evaluate the tumor-targeting ability, both wild-type hPK5 and NGR-hPK5 were (99 m)Tc-labeled, for tracking biodistribution in the in vivo tumor model. By planar imaging and biodistribution analyses of major organs, NGR-hPK5 was found localized to tumor tissues at a higher level than wild-type hPK5 (approximately 3-fold). Finally, the effects of wild-type hPK5 and NGR-modified hPK5 on tumor growth were investigated in two tumor model systems. NGR modification improved tumor localization and, as a consequence, effectively inhibited the growth of mouse Lewis lung carcinoma (LLC) and human colorectal adenocarcinoma (Colo 205) cells in tumor-bearing mice. CONCLUSIONS/SIGNIFICANCE: These studies indicated that the addition of an APN targeting peptide NGR sequence could improve the ability of hPK5 to inhibit angiogenesis and tumor growth.
39
ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESIS
Judah Folkman, Ezio Merler, Charles M. Abernathy et al. · The Journal of Experimental Medicine · 1971 · 1.7K citations · Full text
Medicine, Cancer Biology, Oncology +15
Anti-cancer activity of targeted pro-apoptotic peptides
H. Michael Ellerby, Wadih Arap, Lisa Ellerby et al. · Nature Medicine · 1999 · 930 citations
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.
Renata Pasqualini, Erkki Koivunen, Renate Kain et al. · PubMed · 2000 · 867 citations
Medicine, Oncology, Pharmacology +16
CD13 is a therapeutic target in human liver cancer stem cells
Naotsugu Haraguchi, Hideshi Ishii, Koshi Mimori et al. · Journal of Clinical Investigation · 2010 · 606 citations · Full text
Medicine, Cell Biology, Oncology +17